Articles Related to Thrombocytopenia
Thrombocytopenia is a reduction in the platelet count below the reference range of 150 x 109 /L. It is the second commonest hematologic disorder, following anaemia in pregnancy. Women with thrombocytopenia in pregnancy have a higher tendency to bleed; postpartum haemorrhage is a major cause of maternal mortality in our setting.
Successful use of Eltrombopag for Management of Temozolomide Related Severe Prolonged Thrombocytopenia and Aplastic Anaemia in The Treatment of Glioblastoma Multiforme (GBM) in a Regional Centre: A Case Report and Literature Review
Temozolomide is an orally administered chemotherapeutic drug used concurrently with radiation for the treatment of newly diagnosed glioblastoma. Although the addition of Temozolomide has shown to improve overall survival, it is commonly associated with haematological complications. Eltrombopag is an oral thrombopoietin (TPO) receptor agonist that is also used off-label for temozolomide-induced aplastic anaemia.
The novel coronavirus, SARS-COV-2, that has emerged as pneumonia (COVID-19), is raising global concern. The current study aimed to quantify the diagnostic value of platelet count for the disease severity assessment.
Successful Treatment of Acquired Amegakaryocytic Thrombocytopenia (AAT) with Cyclosporine and Eltrombopag: A Case Report
Acquired amegakaryocytic thrombocytopenia is an unusual hematological disorder characterized by severe thrombocytopenia in association with a marked decrease, or the absence, of megakaryocytes in bone marrow. Its pathogenesis is not well understood and its clinical course is variable. Several treatments have been used, producing different responses. We present a case that was successfully treated with a calcineurin inhibitor combined with a thrombopoiesis-stimulating agent.
Evaluating the Effect of Oprelvekin on Cardiac Repolarization in Subjects with Chemotherapy-Induced Thrombocytopenia: An Observational Chart Review of a Phase 2 Clinical Trial in Laredo, Texas
This study tested for the cardiac effects of Oprelvekin, recombinant human interleukin-11, a thrombopoietic growth factor, in patients afflicted with chemotherapy-induced thrombocytopenia (platelet count<50,000 cells/ul). Chart-reviews of patients fulfilling the inclusion criteria of: 18-75 yrs of age, non-myeloid malignancy, with adequate hematologic, hepatic and renal parameters and normal electrocardiograms that were enrolled in this phase 2 trial were analyzed. Patients of child-bearing potential agreed to be on a reliable form of birth control for the duration of the study. Results on 4 patients suggest that Oprelvekin does not cause atrial nor ventricular arrhythmia, a rare severe cardiac side effect, in treating patients with chemotherapy-induced thrombocytopenia.
Preeclampsia is clinically defined by hypertension and proteinuria, with or without pathologic edema that occurs after 20 weeks’ gestation, but can also present up to 4-6 weeks post-partum. Worldwide, incidence of preeclampsia is 5-14 percent of all pregnancies, while severe preeclampsia can develop to about 25 percent of all cases of preeclampsia.
Attributable Healthcare Cost and Length of Hospital Stay Associated with Heparin-Induced Thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is a serious adverse drug reaction associated with an increased length of hospital stay (LOS) and utilization of healthcare services and even more so if heparin-induced thrombotic thrombocytopenia (HITT) occurs.
Warfarin is the most frequently prescribed oral anticoagulant in the United States. Its indications range from treatment of deep venous thrombosis and pulmonary emboli to the prophylaxis and treatment of thromboembolic conditions associated with atrial fibrillation and cardiac valve replacement. While bleeding is the most commonly encountered complication warfarin induced skin necrosis (WISN) can be a rare complication. Extensive skin and deeper tissue necrosis may be encountered requiring multiple surgical debridement and reconstructive procedures along with the medical management.
Relapsed high-grade gliomas (HGG) respond poorly to known chemotherapeutic agents with a median survival of 3 to 6 months. Several phase II trials of Bevacizumab for salvage therapy, reported excellent response rates. The optimal dose of Bevacizumab in GBM has not been defined to date. We performed a prospective phase II trial of bevacizumab using 5 mg/kg every 2 weeks.
In this report, we present a case of dermatophytosis in a dog seropositive for Ehrlichia spp.Mild annular skin lesions observed on initial presentation persisted and became worse during the course of antibiotic therapy. Microscopic examination of the fungal culture of skin scrapings revealed infection with Microsporum gypseum. The patient fully recovered following treatment with topical 1% clotrimazole and antifungal shampoo.
Bone marrow transplant (BMT) recipients often require parenteral nutrition (PN) to meet their nutrient needs. While general guidelines for the provision of PN support by nutrition support teams (NSTs) have been shown to decrease inappropriate PN use, recommendations for nutrition in BMT recipients are lacking.